ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gary Gordon, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 59324
Scottsdale, Arizona, United States
- Site Reference Id/investigator# 26523
Atlanta, Georgia, United States
- Site Reference Id/investigator# 26522
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2010
- Primary completion
- 30 Jun 2013
- Completion
- 30 Jun 2013
- Last update posted
- 20 Nov 2017
- Registered enrollment
- 52
- Registry id
- NCT01110473
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.